Literature DB >> 18316622

Equilibrium between host and cancer caused by effector T cells killing tumor stroma.

Bin Zhang1, Yi Zhang, Natalie A Bowerman, Andrea Schietinger, Yang-Xin Fu, David M Kranz, Donald A Rowley, Hans Schreiber.   

Abstract

The growth of solid tumors depends on tumor stroma. A single adoptive transfer of CD8(+) CTLs that recognize tumor antigen-loaded stromal cells, but not the cancer cells because of MHC restriction, caused long-term inhibition of tumor growth. T cells persisted and continuously destroyed CD11b(+) myeloid-derived, F4/80(+) or Gr1(+) stromal cells during homeostasis between host and cancer. Using high-affinity T-cell receptor tetramers, we found that both subpopulations of stromal cells captured tumor antigen from surrounding cancer cells. Epitopes on the captured antigen made these cells targets for antigen-specific T cells. These myeloid stromal cells are immunosuppressive, proangiogenic, and phagocytic. Elimination of these myeloid cells allowed T cells to remain active, prevented neovascularization, and prevented tumor resorption so that tumor size remained stationary. These findings show the effectiveness of adoptive CTL therapy directed against tumor stroma and open a new avenue for cancer treatments.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18316622     DOI: 10.1158/0008-5472.CAN-07-5324

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

Review 1.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

2.  Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors.

Authors:  David H Aggen; Adam S Chervin; Francis K Insaidoo; Kurt H Piepenbrink; Brian M Baker; David M Kranz
Journal:  Protein Eng Des Sel       Date:  2010-12-14       Impact factor: 1.650

Review 3.  Environment-mediated drug resistance: a major contributor to minimal residual disease.

Authors:  Mark B Meads; Robert A Gatenby; William S Dalton
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

Review 4.  Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anti-cancer therapy?

Authors:  Tamas A Gonda; Andrea Varro; Timothy C Wang; Benjamin Tycko
Journal:  Semin Cell Dev Biol       Date:  2009-10-17       Impact factor: 7.727

5.  Cancer-immune equilibrium: questions unanswered.

Authors:  Alka Bhatia; Yashwant Kumar
Journal:  Cancer Microenviron       Date:  2011-05-24

6.  Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.

Authors:  Ainhoa Arina; Theodore Karrison; Eva Galka; Karin Schreiber; Ralph R Weichselbaum; Hans Schreiber
Journal:  Cancer Immunol Res       Date:  2017-01-11       Impact factor: 11.151

7.  Immunotherapy of tumor with vaccine based on basic fibroblast growth factor-activated fibroblasts.

Authors:  Xiuying Li; Yongsheng Wang; Yuwei Zhao; Hengxiu Yang; Aiping Tong; Chengjian Zhao; Huashan Shi; Yang Li; Zhenlin Wang; Yuquan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-10       Impact factor: 4.553

Review 8.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

Review 9.  Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family.

Authors:  H Michael Shepard; Cathleen M Brdlik; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

Review 10.  Inflammation and pancreatic cancer: disease promoter and new therapeutic target.

Authors:  Shin Hamada; Atsushi Masamune; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2013-11-30       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.